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Background: KL-6 is a high-molecular-weight glycoprotein classified as human Mucin-1 (MUC1).
KL-6 has been reported to be a sensitive biomarker for interstitial lung diseases (ILDs) in the
Japanese population. It is also known that polymorphisms in the MUC1 gene affect serum levels
of KL-6. This study was conducted to evaluate serum levels of KL-6 and MUC1 polymorphisms in
both German and Japanese populations.
Methods: Serum levels of KL-6 were measured in 267 patients with ILDs (152 German and 115
Japanese) and 186 healthy subjects (HS) (76 German and 110 Japanese). In addition, rs4072037
single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction. The
optimal cutoff values for discriminating patients with ILDs from HS was determined by receiver
operating characteristic analysis based on ethnicity and rs4072037 genotypes.
Results: The serum KL-6 levels in patients with ILDs were significantly higher compared with HS
in both the German and the Japanese cohorts (both p< 0.001). The discriminating cutoff value
of serum KL-6 in the German cohort was significantly higher than the value in the Japanese
cohort. The difference in the serum levels of KL-6 was significantly associated with the
rs4072037 genotype distribution.
Conclusions: Even in the German cohort, the serum KL6 levels were significantly higher in
patients with ILDs than HS. Because of differences in the genotype distribution of2 257 5196; fax: þ81 82 255 7360.
a-u.ac.jp (N. Hattori).
2 Elsevier Ltd. All rights reserved.
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Ethnic and genetic differences in serum KL-6 levels 1757rs4072037, the KL-6 cutoff value for the German cohort that discriminated patients with ILDs
from HS was significantly higher than the value in the Japanese cohort.
ª 2012 Elsevier Ltd. All rights reserved.Background
The idiopathic interstitial pneumonias (IIPs) are a group of
diffuse parenchymal lung diseases characterized by inter-
stitial involvement resulting from various patterns of
inflammation and fibrosis of unknown cause. The prevalence
of IIPs has been generally reported to be 5e20 per 100,000
persons.1e4 Since therapy with corticosteroids and/or
immunosuppressants is largely ineffective for advanced
stages of interstitial lung diseases (ILDs), early diagnosis is of
utmost importance.5,6 High-resolution computed tomog-
raphy (HRCT) and/or surgical lung biopsy (SLB) are at present
the fundamental modalities for definitive diagnosis of IIPs.7,8
Compared to these diagnostic methods, an optimal
biomarker for discriminating patients with IIPs from healthy
subjects should be less invasive, more rapid and reproduc-
ible, and easier to obtain from patients.9
We previously developed a murine IgG1 monoclonal anti-
body that recognized a sialylated sugar chain, designated
Krebs von den lungen-6 (KL-6). KL-6 is a high-molecular-
weight glycoprotein and has been classified as a human
Mucin-1 (MUC1).10e13 We have demonstrated that KL-6 is
a useful biomarker for discriminating ILDs from other benign
lung diseases, evaluating disease activity, predicting disease
outcome, and monitoring the clinical course.10,13,14 Because
of these findings, KL-6 was approved in 1999 by the Japanese
Health Insurance Program as a diagnostic biomarker for ILDs,
and has beenmeasured in over 1,800,000 samples per year in
Japan. In most countries, however, KL-6 is currently
unavailable for clinical practice, and the use of KL-6 as
a serum biomarker for ILDs among non-Japanese populations
remains limited. We recently found indications that circu-
lating levels of KL-6 were higher in European cohorts than
levels reported earlier from the Japanese population.15,16
Furthermore, it has been reported that the serum levels of
KL-6 in patients with sarcoidosis vary according to the status
of rs4072037, a single nucleotide polymorphism (SNP) on
exon 2 of the MUC1 gene.17 KL-6 levels were highest for the
G/G genotype, lowest for the A/A genotype, and at inter-
mediate levels for the A/G genotype. In addition, available
data from the HapMap database indicate that the genotypes
of this polymorphism are found at different frequencies in
Caucasian and Japanese ethnic groups.18
Based on these observations, we hypothesized that
there might be differences in the circulating KL-6 levels of
patients with ILDs and healthy subjects between European
(e.g., German) and Japanese populations. To test this
hypothesis, we evaluated the serum KL-6 levels and
determined the rs4072037 genotypes in MUC1 in both
German and Japanese cohorts that included patients with
ILDs and healthy subjects. The cutoff values for serum KL-6
levels that discriminated patients with ILDs from healthy
subjects were determined and compared between the
German and Japanese cohorts, and associations between
serum KL-6 levels and rs4072037 genotypes in MUC1 were
also analyzed.Methods
Study subjects
Between February 2007 and December 2011, 152 consecutive
patients with ILDs at Ruhrlandklinik, University Hospital
(Essen, Germany) and 115 patients with ILDs at Hiroshima
University Hospital (Hiroshima, Japan) were enrolled in this
study. Seventy-six German and 110 Japanese healthy volun-
teers were also included as healthy control subjects. Each
patientwith ILDunderwentaphysical examination,pulmonary
function tests, chest computed tomography (CT), and/or SLB.
Diagnoses of IIPs were made based on the criteria of the
American Thoracic Society (ATS)/European Respiratory
Society (ERS) published in 2002, which included characteristic
clinical and/or CT findings and/or histological findings.7 Each
healthy volunteer underwent pulmonary function tests and
chest X-ray studies, and thosewithapparent lungdisease, such
as ILDs or chronic obstructive pulmonary disease (COPD), were
excluded.This studywasapprovedbytheEthicsCommitteesof
Ruhrlandklinik (IRB 06-3170) andHiroshima University Hospital
(IRB 326) and conducted in accordance with the ethical stan-
dards established in the Helsinki Declaration of 1975. All
patients and healthy volunteers gave informed consents in
writing and permission to use their samples.
Lung function values
Physiologic assessment included measurements of thoracic
gas volume, total lung capacity, forced vital capacity (FVC),
forced expiratory volume in 1 second (FEV1), and single-
breath diffusing capacity of the lung for carbon monoxide
(DLCO), as previously described.
16 The protocol for lung func-
tion measurements conformed to ATS recommendations.19
Measurement of serum KL-6 levels
Serum samples were obtained from 267 patients with ILDs
and 186 healthy subjects and stored at 80 C until
analyzed. Serum KL-6 levels were measured by a sandwich-
type electrochemiluminescence immunoassay (ECLIA) using
a Picolumi 8220 Analyzer (EIDIA Co. Ltd. Tokyo, Japan), as
previously described.20,21
DNA preparation and genotype analyses of MUC1
rs4072037
We extracted DNA from peripheral whole venous blood
samples using the phenol-chloroform extraction and
ethanol precipitation methods, as previously described.22
The rs4072037 genotype was determined using a real-time
polymerase chain reaction (RT-PCR) method. We used
a commercially available SNP genotyping assay (TaqMan
SNP Genotyping Assay C 27532642-10; Life Technologies
Table 1 The clinical characteristics of study subjects.
Patients
with ILDs
German Japanese p value
Number of
subjects
152 115
Age, years 67.4 0.8 67.5 0.8 0.659
Gender,
male/female
94/58 77/38 0.388
Smoking status,
non/Ex/Cu/
unknown
68/56/15/13 44/55/14/2 0.282
VC, percent
predicted
67.3 1.6 72.0 2.1 0.103
DLCO, percent
predicted
48.3 1.5 47.5 1.8 0.642
Diagnostic categories of ILDs
IPF, n 92 61 0.320
NSIP, n 44 34
COP, n 6 10
Drug-induced
ILD, n
10 10
Healthy subjects German Japanese p Value
Number of
subjects
76 110
Age, years 45.1 1.2 45.8 0.7 0.345
Gender,
male/female
33/43 62/48 0.083
Smoking, non/Ex/
Cu/ unknown
36/9/19/12 66/15/29 0.876
Data are shown as mean SEM. Statistical significance was
tested by ManneWhitney U test or Chi-square test. ILD, inter-
stitial lung disease; Non, non-smoker; Ex, ex-smoker; Cu,
current smoker; VC, vital capacity; DLCO, diffusing capacity of
the lung for carbon monoxide; IPF, idiopathic pulmonary
fibrosis; NSIP, nonspecific interstitial pneumonia; COP, crypto-
genic organizing pneumonia.
1758 Y. Horimasu et al.Corp., Carlsbad, California, USA) and the Applied Bio-
systems 7500 Fast RT-PCR System (Life Technologies Corp.).
Statistical analysis
Individual variables for two groups were analyzed by the
ManneWhitney U-test or chi-square test. The significance
levels formultiplepairwise comparisonswere set according to
Bonferroni’s correction. Linear regression analysis was con-
ducted to study the independent effect of age, gender,
smoking status, ethnicity, diagnostic category, lung function
values, rs4072037 genotype, and presence or absence of ILD
on serum KL-6 levels. The usefulness of serum KL-6 as a diag-
nostic biomarker for ILDs was assessed by receiver operating
characteristic (ROC) analysis, and the optimal cutoff values
fordiscriminating thepatientswith ILDs fromhealthy subjects
were determined. All statistical analyses were performed
using SPSS forWindows, version 18.0 (SPSS Inc. Chicago, USA).
Results
Serum KL-6 levels were significantly higher in
healthy German subjects than in healthy Japanese
subjects
The clinical characteristics of 267 patients with ILDs (152
Germans and 115 Japanese) and 186 healthy subjects (76
Germans and 110 Japanese) are shown in Table 1. Serum KL-6
levels in patients with ILDs and in healthy subjects are shown
in Fig. 1a. The mean serum KL-6 levels in healthy German
subjects (German HS), German patients with ILDs (German
ILDs), healthy Japanese subjects (JapaneseHS), andJapanese
patients with ILDs (Japanese ILDs) were 331.5 13.6 U/ml
(mean SEM), 1831.0 110.4 U/ml, 233.7 8.1 U/ml, and
1519.0 97.9 U/ml, respectively. In both German and Japa-
nesecohorts, the serumKL-6 levelswere significantlyhigher in
patients with ILDs than in healthy subjects (p< 0.001 and
p< 0.001, respectively). Furthermore, serum KL-6 levels in
German HSwere found to be significantly higher than those in
JapaneseHS (p< 0.001). The serumKL-6 levels inGerman ILDs
tended to be higher than the levels in Japanese ILDs, although
the difference was not statistically significant. We also
compared serum KL-6 levels between German and Japanese
patients within each of the following diagnostic categories of
ILD: idiopathic pulmonary fibrosis (IPF), nonspecific intersti-
tial pneumonia (NSIP), cryptogenic organizing pneumonia
(COP), and drug-induced ILD. There were no significant
differences in serumKL-6 levels according to the ethnicities of
patients with each type of ILD (Fig. 1b).
The optimal cutoff value for serum KL-6 levels that
discriminated patients with ILDs from healthy
subjects was higher in the German cohort than in
the Japanese cohort
To evaluate the ability of the serum KL-6 level for
discriminating patients with ILDs from HS, ROC curves were
drawn for each cohort. The area under the ROC curve (AUC)
was 0.967 (p< 0.001) for the German cohort (Fig. 1c) and
0.987 (p< 0.001) for the Japanese cohort (Fig. 1d). Basedon these ROC analyses, the optimal cutoff value for the
serum KL-6 level showing the best sensitivity and specificity
was 659 U/ml for the German cohort and 461 U/ml for the
Japanese cohort (Table 2).
Distribution of the rs4072037 genotypes in MUC1
was different in the German and Japanese cohorts
DNA was extracted from blood samples in 193 out of 267
patients with ILDs (113 Germans and 80 Japanese) and 145
out of 186 HS (35 Germans and 110 Japanese), and the
rs4072037 genotypes of MUC1 were determined. The
distributions of the SNPs in the German and Japanese
cohorts are shown in Table 3. In both the German and
Japanese cohorts, the distributions of the rs4072037 geno-
types were in HardyeWeinberg equilibrium (pZ 0.679 and
pZ 0.839, respectively). In addition, the distributions of
the rs4072037 genotypes in both HS and patients with ILDs
varied with ethnicity (Table 3, p< 0.001 and p< 0.001,
respectively); the frequency of the G/G genotype was
Figure 1 Serum levels of KL-6 according to ethnicity, (a)
compared between healthy subjects and patients with inter-
stitial lung diseases (ILDs), and (b) compared within each
diagnostic category of ILD. Each point represents the serum KL-
6 level in the studied subjects (HS, healthy subjects; ILDs,
patients with interstitial lung diseases; IPF, idiopathic pulmo-
nary fibrosis; NSIP, nonspecific interstitial pneumonia; COP,
cryptogenic organizing pneumonia; drug-ILD, drug-induced ILD;
NS, not significant). The horizontal bars represent the mean
values. (a) The significance level was set at aZ 0.0125 (four
comparisons in four groups). ***p< 0.001 (ManneWhitney U
test). Receiver operating characteristic (ROC) analyses were
performed for patients with ILDs and healthy subjects in (c)
German and (d) Japanese cohorts. Arrows at the top left corner
show the points with best sensitivities and specificities.
Table 2 Optimal cutoff values of serum KL-6 according to
ethnicity or rs4072037 genotype.
Ethnicity rs4072037 Genotype
German Japanese A/A A/G G/G
Cutoff value,
U/ml
659 461 397 461 503
Sensitivity 0.862 0.939 0.958 0.986 1.000
Specificity 1.000 1.000 1.000 0.981 1.000
Accuracy 0. 908 0.969 0.977 0.984 1.000
The optimal cutoff values are determined as the serum levels of
KL-6 which show the best sensitivity and specificity in ROC
analysis. AccuracyZ (true positivesþ true negatives)/total
subjects.
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was significantly lower in the German cohort than in the
Japanese cohort. However, the distributions of the
rs4072037 genotypes did not differ between HS and patients
with ILDs in either the German or Japanese cohorts.
The optimal cutoff values for serum KL-6 levels that
discriminated patients with ILDs from healthy
subjects were different, depending on the
rs4072037 genotype
To determine the effects of rs4072037 SNPs on serum KL-6
levels in healthy subjects, serum KL-6 levels were
compared between the patients with rs4072037 A/A, A/G,
and G/G genotypes. Because there were no significant
ethnic differences between the serum KL-6 levels of
patients with each genotype (data not shown), both
German and Japanese subjects were included in each
genotype analysis. The mean serum KL-6 levels in HS were
determined to be 210.4 7.6 U/ml for the A/A genotype,
286.9 13.8 U/ml for the A/G genotype, and
354.5 361 U/ml for the G/G genotype. As shown in
Fig. 2a, the serum KL-6 levels in the HS with A/G or G/G
genotypes were significantly higher than the serum KL-6
levels in the subjects with the A/A genotype (p< 0.001
and pZ 0.001, respectively).
The serum KL-6 levels were then compared between the
ILD patients with rs4072037 A/A, A/G, and G/G genotypes.
The mean serum KL-6 levels in patients with ILDs were
1421.2 99.7 U/ml for the A/A genotype, 2129.0 176.9 U/
ml for the A/G genotype, and 1915.6 244.8 U/ml for the G/
G genotype. As shown in Fig. 2a, the serum KL-6 levels were
significantly higher in ILD patients with the A/G genotype
than in patients with the A/A genotype (p 0.001). We also
compared the serum KL-6 levels between patients with
rs4072037 A/A, A/G, and G/G genotypes within each diag-
nostic category of ILD (IPF, NSIP, COP, and drug-induced ILD).
There were no significant differences in serum KL-6 levels
according to rs4072037 genotypes of patients with each type
of ILD (Fig. 2b).
To evaluate the ability of serum KL-6 levels to discrimi-
nate patients with ILDs from HS within each genotype, ROC
curves were drawn for each rs4072037 genotype. The AUC
valueswere 0.991 (95%CI, 0.000e1.000,p< 0.001) for theA/
A genotype (Fig. 2c), 0.990 (95% CI, 0.000e1.000, p< 0.001)
for the A/G genotype (Fig. 2d), and 1.000 (95% CI,
1.000ee1.000, p< 0.001) for the G/G genotype (Fig. 2e). As
shown in Table 2, the optimal cutoff values of serum KL-6
levels that discriminated patients with ILDs from HS were
determined to be 397 U/ml for the A/A genotype, 461 U/ml
for the A/G genotype, and 503 U/ml for the G/G genotype.
Serum KL-6 levels are independently correlated
with the rs4072037 genotype in MUC1
To obtain more information on variables that might affect
serum KL-6 levels, correlations between the serum level of
KL-6 and clinical characteristics, including age, gender,
smoking status, ethnicity, specific rs4072037 genotype, and
the presence or absence of ILD, were examined using linear
regression analysis. Univariate analysis confirmed that older
Table 3 Frequency of each genotype of rs4072037.
Patients with ILDs Total A/A (%) A/G (%) G/G (%)
German
Number of subjects 113 38 (33.6) 49 (43.4) 26 (23.0)
Standardized residuals 5.3 2.4 4.3
Japanese
Number of subjects 80 58 (72.5) 21 (26.3) 1 (1.2)
Standardized residuals 5.3 2.4 4.3
Healthy subjects Total A/A (%) A/G (%) G/G (%)
German
Number of subjects 35 9 (25.7) 17 (48.6) 9 (25.7)
Standardized residuals 4.0 1.7 4.3
Japanese
Number of subjects 110 71 (64.5) 36 (32.8) 3 (2.7)
Standardized residuals 4.0 1.7 4.3
p< 0.001, tested by chi-square test.
ILDs, interstitial lung diseases.
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Z 4.090, p 0.001), German ethnicity (BZ 730.926,
SEZ 125.844, p 0.001), the rs4072037 G/G genotype
(BZ 333.670, SEZ 93.596, p< 0.001), and the presence of
ILD (BZ 1489.534, SEZ 104.439, p 0.001) were signifi-
cantly correlated with higher serum KL-6 levels (Table 4a);
and multivariate analysis revealed that the rs4072037 G/G
genotype (BZ 213.973, SEZ 81.802, pZ 0.009) and the
presence of ILD (BZ 1533.652, SEZ 159.022, p 0.001)
were independently correlated with higher serum KL-6
levels. To further evaluate the correlation between the
serum KL-6 levels and clinical characteristics, we performed
subgroupanalyses basedon subjectswithorwithout ILDs. For
the HS, univariate analysis confirmed that older age
(BZ 2.648, SEZ 0.853, pZ 0.002), German ethnicity
(BZ 63.969, SEZ 18.190, pZ 0.001) and rs4072037 G/G
genotype (BZ 69.949, SEZ 11.162, p 0.001) were signifi-
cantly correlated with higher serum KL-6 levels (Table 4b);
andmultivariate analysis revealed that older age (BZ 3.035,
SE Z 0.741, p < 0.001) and the rs4072037 G/G genotype
(BZ 64.924, SEZ 11.589, p< 0.001) were independently
correlated with higher serum KL-6 levels. For the patients
with ILDs, univariate analysis demonstrated that decreased%
VC (BZ 13.082, SEZ 5.681, pZ 0.006), decreased %DLCO
(BZ 12.664, SEZ 5.681, pZ 0.027), and rs4072037 G/G
genotype (BZ 358.590, SEZ 124.140, pZ 0.004) were
significantly correlated with higher serum KL-6 levels (Table
4c); and multivariate analysis revealed that only the
rs4072037 G/G genotype (BZ 301.665, SEZ 130.177,
pZ 0.022) was independently correlated with higher serum
KL-6 levels.Discussion
In this study, we found in both the German and Japanese
cohorts that serum KL-6 levels were significantly higher in
patients with ILDs than in healthy subjects. We also foundthat the optimal cutoff value for the serum KL-6 level that
discriminated patients with ILDs from healthy subjects was
higher in the German cohort than in the Japanese cohort.
The distribution of the rs4072037 genotypes in MUC1 was
shown to differ between the German and Japanese cohorts.
In addition, multivariate regression analyses, which
included both German and Japanese subjects, revealed
that a specific rs4072037 genotype in MUC1 and the pres-
ence of an ILD independently affected serum KL-6 levels.
Our study showed that the difference in the cutoff
values for serum KL-6 levels of German and Japanese
cohorts that discriminated patients with ILDs from healthy
subjects was at least in part due to different distributions
of the rs4072037 genotypes in MUC1. The G/G genotype was
more common in the German cohort, and the A/A genotype
was more common in the Japanese cohort. The distribu-
tions of the rs4072037 genotypes in the German and Japa-
nese cohort were shown to be similar to the respective
distributions in CEU (Utah residents with ancestry from
northern and western Europe) and in JPT (Japanese in
Tokyo, Japan) populations, which are reported in the
HapMap database.18
The rs4072037 SNP is located in exon 2 of MUC1. Previous
studies reported that this SNP regulates splicing site
selection and is in strong linkage disequilibrium with vari-
able numbers of tandem repeats (TRs) in MUC1. The G
allele correlates with a large number of TRs and the A allele
correlates with a small number of TRs.23,24 Because the
sialylated sugar chains on MUC1, which are believed to be
recognized by the anti-KL-6 monoclonal antibody ,11,12 are
known to be abundant in the TR domain, larger numbers of
TRs may contain more KL-6 antigen, resulting in higher
serum KL-6 levels.25e27 In agreement with these previous
reports, our data showed that the serum KL-6 levels in the
A/G and G/G genotype cohorts were higher than those in
the A/A genotype cohort.17 Based on these results, we
hypothesize that the higher levels of serum KL-6 in the
German compared with the Japanese cohort may be caused
Figure 2 Serum levels of KL-6 according to rs4072037 genotype, (a) compared between healthy subjects and patients with
interstitial lung diseases (ILDs), and (b) compared within each diagnostic category of ILD. Each point represents the serum KL-6
level in the studied subjects (HS, healthy subjects; ILDs, patients with interstitial lung diseases; IPF, idiopathic pulmonary
fibrosis; NSIP, nonspecific interstitial pneumonia; COP, cryptogenic organizing pneumonia; drug-ILD, drug-induced ILD; NS, not
significant). The horizontal bars represent the mean values. (a) The significance level was set at aZ 0.0056 (nine comparisons
in six groups). **p< 0.0056, ***p< 0.001 (ManneWhitney U test). (b) The significance level was set at aZ 0.017 (three
comparisons in three groups) for IPF, NSIP, and drug-ILD, and at aZ 0.05 (Bonferroni’s correction was not adopted) for COP.
Receiver operating characteristic (ROC) analyses were performed between patients with ILDs and healthy subjects in (c) A/A
cohort, (d) A/G cohort, and (e) G/G cohort of rs4072037. Arrows at the top left corner show the points with best sensitivities
and specificities.
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Table 4 Linear regression analysis for serum KL-6.
a. Whole studied subjects Regression
coefficient
Standard
error
p Value
Univariate analysis
Age, years 35.413 4.090 <0.001
Gender, female
vs male
135.546 133.043 0.309
Smoking, Non vs
Ex vs Cu
23.001 88.610 0.795
Ethnicity, Japanese
vs German
730.926 125.844 <0.001
rs4072037, A/A vs
A/G vs G/G
333.670 93.596 <0.001
With or without
ILDs, HS vs ILDs
1489.534 104.439 <0.001
Multivariate analysis
Age, years 4.989 5.263 0.344
Ethnicity, Japanese
vs German
117.823 120.173 0.328
rs4072037, A/A vs
A/G vs G/G
213.973 81.802 0.009
With or without
ILDs, HS vs ILDs
1533.652 159.022 <0.001
b. Healthy subjects Regression
coefficient
Standard
error
p Value
Univariate analysis
Age, years 2.648 0.853 0.002
Gender, female
vs male
11.760 16.229 0.470
Smoking, Non vs
Ex vs Cu
1.159 9.300 0.901
Ethnicity, Japanese
vs German
63.969 18.190 0.001
rs4072037, A/A vs
A/G vs G/G
69.949 11.162 <0.001
Multivariate analysis
Age, years 3.035 0.741 <0.001
Ethnicity, Japanese
vs German
28.572 17.447 0. 104
rs4072037, A/A vs
A/G vs G/G
64.924 11.589 <0.001
c. Patients with ILDs Regression
coefficient
Standard
error
p Value
Univariate analysis
Age, years 10.616 8.997 0.239
Gender, female
vs male
55.201 188.244 0.770
Smoking, Non vs
Ex vs Cu
111.173 135.264 0.412
VC, percent
predicted
13.082 4.722 0.006
DLCO, percent
predicted
12.664 5.681 0.027
Table 4 (continued )
Ethnicity, Japanese
vs German
355.953 181.940 0.052
Diagnostic category,
drug-ILD vs COP vs
IPF vs NSIP
195.010 102.851 0.059
rs4072037, A/A vs
A/G vs G/G
358.590 124.140 0.004
Multivariate analysis
VC, percent
predicted
2.219 5.72 0.699
DLCO, percent
predicted
11.682 6.366 0.069
rs4072037, A/A
vs A/G or G/G
301.665 130.177 0.022
Non, non-smoker; Ex, ex-smoker; Cu, current smoker; HS,
Healthy subjects; ILDs, interstitial lung diseases; VC, vital
capacity; DLCO, diffusing capacity of the lung for carbon
monoxide; drug-ILD, drug-induced interstitial lung disease;
COP, cryptogenic organizing pneumonia; IPF, idiopathic
pulmonary fibrosis; NSIP, nonspecific interstitial pneumonia.
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in the German than in the Japanese cohort.
To evaluate the ability of serum KL-6 levels based on
ethnicity and genotype for discriminating patients with ILDs
from healthy subjects, we performed ROC analysis for each
rs4072037 genotype. Importantly, the AUC value for each
rs4072037 genotype (Fig. 2cee; 0.991 for A/A, 0.990 for A/
G, and 1.000 for G/G, respectively) was higher than the
AUC value for each ethnicity (Fig. 1c, d; 0.967 for German
and 0.987 for Japanese cohort, respectively). In addition,
the sensitivity, specificity, and accuracy tended to be
higher in genotype-based analysis than in ethnicity-based
analysis (Table 2). These data suggest that the cutoff
values of serum KL-6 levels based on rs4072037 genotypes
show better abilities of discriminating patients with ILDs
from healthy subjects than the cutoff values based on
ethnicity. Furthermore, the rs4072037 G/G genotype was
independently correlated with serum KL-6 levels, whereas
ethnicity was not. Based on these results, we can conclude
that the different cutoff values for serum KL-6 levels in the
German and Japanese cohorts that discriminated patients
with ILDs from healthy subjects were at least partially
a result of the different distributions of rs4072037 geno-
types in these cohorts; and, ideally, a cutoff value for the
serum KL-6 levels that discriminates patients with ILDs from
healthy subjects should be based on the rs4072037 geno-
type. However, primarily because of the expense, it may
not be clinically feasible to determine the rs4072037
genotype of every patient with ILD. Therefore, we believe
that cutoff values of serum KL-6 levels that discriminate
patients with ILDs from healthy individuals should be
determined on the basis of ethnicity.
Another interesting finding of this study was that the
serum KL-6 levels in patients with ILDs were inversely
correlated with the values for %DLco and %VC (Table 4c).
This finding is consistent with the results of previous studies
demonstrating the correlation between serum KL-6 and
parameters of lung function in patients with various types
Ethnic and genetic differences in serum KL-6 levels 1763of ILDs.28e31 Interestingly, previous studies from our labo-
ratory demonstrated that KL-6 itself has chemotactic and
antiapoptotic effects on fibroblasts, and additive effects on
the proliferative and antiapoptotic activity of transforming
growth factor-b toward fibroblasts.11,32 These observations
suggest that KL-6 may be involved in the fibrotic processes
in the lung that lead to decreased values of %DLco and %VC.
On the other hand, there were no significant differences
in the distributions of rs4072037 genotypes between
healthy subjects and patients with ILDs. This finding indi-
cates that there is no correlation between rs4072037
genotype and susceptibility to ILDs, although correlations
between rs4072037 genotypes and susceptibility to dry-eye
syndrome and gastric cancer have been reported.33,34
There are a number of limitations to this study. First, the
sizes of the cohorts were relatively small, particularly with
regard to the number of subjects available for analysis of
rs4072037 genotypes. In addition, the patients with ILDs
were older than the healthy subjects. However, multivariate
analysis of all the subjects demonstrated that serum KL-6
levels did not correlate with age. Second, the relationship
between radiographicmanifestations of chest CT images and
KL-6 levels was not analyzed. This was because we were
unable to assess the extent of fibrosis using standardized
criteria for both German and Japanese patients with ILDs,
since different CT scanners with different slice thicknesses
were used at the Ruhrlandklinik in Germany and the Hir-
oshima University Hospital in Japan. Third, only German and
Japanese populations were studied. It remains to be seen
whether the findings of the present study can be applied to
other ethnic groups such as African Americans. Fourth, there
were no follow-up data available for assessing prognostic
values. A prospective follow-up study to investigate the
association between serum KL-6 levels and prognosis is now
being performed for both the German and Japanese cohorts.
Conclusions
In conclusion, we were able to demonstrate that the serum
KL6 levels were significantly higher in patients with ILDs
than in healthy subjects in both the German and Japanese
cohorts. Because of differences in the distribution of
rs4072037 genotypes in the German and Japanese cohorts,
the cutoff value of KL-6 that discriminated patients with
ILDs from healthy subjects was significantly higher in the
German cohort than in the Japanese cohort. Although
promising data were obtained in the present study, further
investigations are needed to determine whether KL-6 can
be used as a diagnostic biomarker in ethnic groups other
than the Japanese.
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